Eli Lilly and Company $LLY Shares Acquired by Private Wealth Partners LLC

Private Wealth Partners LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 12.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,399 shares of the company’s stock after purchasing an additional 612 shares during the period. Private Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $5,802,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Legacy Advisors LLC lifted its position in shares of Eli Lilly and Company by 20.7% during the fourth quarter. Legacy Advisors LLC now owns 2,168 shares of the company’s stock worth $2,330,000 after purchasing an additional 372 shares in the last quarter. Able Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $275,000. Stone Summit Wealth LLC lifted its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Stone Summit Wealth LLC now owns 3,363 shares of the company’s stock worth $3,614,000 after purchasing an additional 40 shares in the last quarter. Measured Risk Portfolios Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $240,000. Finally, Portus Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 6.8% during the fourth quarter. Portus Wealth Advisors LLC now owns 1,789 shares of the company’s stock worth $1,923,000 after purchasing an additional 114 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Bank of America increased their price target on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Rothschild & Co Redburn increased their price target on Eli Lilly and Company from $875.00 to $880.00 and gave the company a “neutral” rating in a report on Friday, April 10th. CICC Research increased their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Scotiabank reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,225.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly’s obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Eli Lilly and Company Trading Down 3.6%

LLY opened at $884.88 on Friday. The stock has a market capitalization of $836.05 billion, a PE ratio of 38.56, a P/E/G ratio of 1.09 and a beta of 0.51. The firm’s fifty day moving average price is $958.83 and its 200 day moving average price is $983.91. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 33.9 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.